Anti-viral therapy of decompensated cirrhosis due to chronic hepatitis B

( views:, downloads: )
WANG Yu-ming()
DENG Guo-hong()
Journal Title:
Volume 1, Issue 04, 2008
Key Word:


  • [1]Pan CQ,Zhang JX.Natural history and clinical consequences of hepatitis B virus infection,Int J Med Sci,2005,2(1):36-40.
  • [2]Perz JF,Armstrong GL,Farrington LA,et al.The contributions of hepatitis B vires and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.J Hepatol,2006,45 (4):529-538.
  • [3]Lai L,Hui CK,Lcong N,et al.Pegylated interferon alpha-2a(40 kDa) in the treatment of chronic hepatitis B.Int J Nanomedicine,2006,1(3):255-262.
  • [4]Lin SM,Sheen IS,Chien RN,et al.Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.Hepatology,1999,29(3):971-975.
  • [5]Hoofnagle JH,Di Bisceglie AM,Waggoner JG,et al.Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.Gastroenterology,1993,104(4):1116-1121.
  • [6]Lai CL,Yuen MF,Hui CK,et al.Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B:results of 24 weeks of therapy.J Meal Virol,2002,67(3):334-338.
  • [7]Berenguer M,Prieto M,Ray6n M,et al.Famciciovir treatment in transplant recipients with HBV-related liver disease:disappointing results.Am J Gastroenterol,2001,96(2):526-533.
  • [8]Dienstag JL,Schiff ER,Wright TL,et al.Lamivudine as initial treatment for chronic hepatitis B in the United States.N Engl J Med,1999,341(17):1256-1263.
  • [9]Perrillo RP,Wright T,Rakela J,et al.A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.Hepatology,2001,33(2):424-432.
  • [10]Leung NW,Lai CL,Chang Tr,et al.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy.Hepatology,2001,33(6):1527-1532.
  • [11]Peters M,Schiff E,Benhamou Y,et al.Adefovir dipivoxil demonstrates antiviral efficacy and clinical benefit in the treatment of lamivudine resistant chronic HBV:an analysis of four clinical trials.Gastroenterology,2002,123(Suppl):71.
  • [12]Shalil AO,Lilly L,Angus P,et al.Entecavir reduces viral load in liver transplant patients who failed prophylaxis or treatment for hepatitis B.Hepatology,2001,34(Suppl):619A.
  • [13]van Bommel F,Wünsche T,Schurmann D,et al.Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.Hepatology,2002,36 (2):507-508.
  • [14]Lim SG,Krastev Z,Ng TM,et al.Randomized,double-blind study of emtrieitabine (FTC) plus elevudine versus FTC alone in treatment of chronic hepatitis B.Antimicrob Agents Chemother,2006,50(5):1642-1648.
  • [15]Lai CL,Loung N,Teo EK,et al.A l-year trial of telbivudine,lamivudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.Gastroenterology,2005,129(2):528-536.
  • [16]Yuen MF,Lai CL.Telbivudine:an upcoming agent for chronic hepatitis B.Expert Rev Anti Infect Ther,2005,3(4):489-494.
  • [17]Rosenau J,Bahr MJ,Tillmann HL,et al.Lamivudine and lowdose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation-possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.J Hepatol,2001,34(6):895-902.
  • [18]Hadizyannis S,Tassopaloas N,Heatheote e,et al.A double blind,randomized placebo-controlled study of adefovir dipvoxil for presumed precore mutant chronic hepatitis B:48 week results.J Hepatol,2002,36(Suppl 1):4.
  • [19]Schiff E,Lai CL,Neuhaus P,et al.Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre and post liver transplantation with lamivudine resistant hepatitis B vires patients.Hepatology,2002,36(Suppl):371A.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615